PT - JOURNAL ARTICLE AU - Martin J. Scurr AU - Wioleta M. Zelek AU - George Lippiatt AU - Michelle Somerville AU - Stephanie E. A. Burnell AU - Lorenzo Capitani AU - Kate Davies AU - Helen Lawton AU - Thomas Tozer AU - Tara Rees AU - Kerry Roberts AU - Mererid Evans AU - Amanda Jackson AU - Charlotte Young AU - Lucy Fairclough AU - Mark Wills AU - Andrew D. Westwell AU - B. Paul Morgan AU - Awen Gallimore AU - Andrew Godkin TI - Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers AID - 10.1101/2021.06.02.21258218 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.02.21258218 4099 - http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258218.short 4100 - http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258218.full AB - Accurate assessment of SARS-CoV-2 immunity in the population is critical to evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T cell responses are a critical feature of the immune response that will likely form a key correlate of protection against COVID-19. Here, we developed and optimised a high-throughput whole blood-based assay to determine the T cell response associated with prior SARS-CoV-2 infection and/or vaccination amongst 156 healthy donors and 67 cancer patients. Following overnight in vitro stimulation with SARS-CoV-2-specific peptides, blood plasma samples were harvested and analysed for TH1-type effector cytokines (IFN-γ and IL-2). Amongst healthy donors, highly significant differential IFN-γ+/IL-2+ SARS-CoV-2-specific T cell responses were seen amongst vaccinated or previously infected COVID-19-positive individuals in comparison to unknown/naïve individuals (P < 0.0001). IL-2 production from T cells in response to SARS-CoV-2 derived antigens was a highly predictive diagnostic assay (P < 0.0001; 96.0% sensitivity, 93.9% specificity); measurement of IFN-γ+ SARS-CoV-2 specific T cell responses was equally effective at identifying asymptomatic (antibody and T cell positive) participants. A single dose of COVID-19 vaccine induced IFN-γ and/or IL-2 SARS-CoV-2-specific T cell responses in 28/29 (96.6%) of healthy donors, reducing significantly to 27/56 (48.2%) when measured in cancer patients (P = 0.0003). Overall, this cost-effective standardisable test ensures accurate and comparable assessments of SARS-CoV-2-specific T cell responses amenable to widespread population immunity testing.Competing Interest StatementMJS is a founder of and holds equity in ImmunoServ Ltd. All other authors declare no conflicts of interest.Funding StatementThis work was funded by two UKRI COVID-19 National Core Study Immunity programmes (Coordinating COVID-19 asymptomatic testing programmes in university settings: providing insight on acquired immunity across the student population (to AnG, LF, MW and ADW), and SARS-CoV-2 Optimal Cellular Assays (to AnG). Additional funding was provided by the MRC, as part of the UK Coronavirus Immunology Consortium (to BPM), and Cancer Research Wales (to MJS, MSS and AnG). AnG is supported by additional grant funding from the Wellcome Trust (grant code 209213/Z/17/Z). AwG is supported by additional grant funding from Cancer Research UK. BPM is supported additional funding by from the UK Dementia Research Institute Cardiff. WMZ is supported by a Health and Care Research Wales Fellowship from the Welsh Government. SEAB is supported by the Wales Cancer Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received ethical approval from the Wales Cancer Bank (WCB No. 21/004), the Newcastle & North Tyneside 2 Research Ethics Committee (IRAS ID: 294246) and Cardiff University School of Medicine Research Ethics Committee (SREC reference: SMREC 21/01). All participants gave written, informed consent prior to inclusion.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.